These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2661281)

  • 41. Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus.
    Henry RR; Brechtel G; Griver K
    J Clin Endocrinol Metab; 1988 May; 66(5):979-86. PubMed ID: 3283164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of type 2 diabetes mellitus in children and adolescents.
    Silverstein JH; Rosenbloom AL
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 6():1403-9. PubMed ID: 11202216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of type 2 diabetes. Early detection of secondary oral treatment failure is important].
    Clauson P; Efendic S
    Lakartidningen; 1999 Jan; 96(3):176-81. PubMed ID: 9951232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of early introduction of intensive insulin therapy on the clinical course in non-obese NIDDM patients.
    Kayashima T; Yamaguchi K; Konno Y; Nanimatsu H; Aragaki S; Shichiri M
    Diabetes Res Clin Pract; 1995 May; 28(2):119-25. PubMed ID: 7587919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-peptide in diabetes mellitus treated with insulin. A 3-year epidemiological study on the island of Falster, Denmark.
    Nielsen NV; Tronier B
    Diabetes Res; 1986 Nov; 3(9):475-8. PubMed ID: 3549123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin deficiency in non-insulin-dependent diabetics.
    Scott RS; Mason DR; Iris FJ; Bremer JR
    Diabetes Res Clin Pract; 1986; 2(6):359-64. PubMed ID: 3545726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.
    Thunander M; Thorgeirsson H; Törn C; Petersson C; Landin-Olsson M
    Eur J Endocrinol; 2011 Feb; 164(2):239-45. PubMed ID: 21088056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remission of insulin requirement in late secondary failure to oral hypoglycemic agents (IRD): results at 24 months and analysis of predictive factors.
    Grulet H; Gross A; Pasqual C; Durlach V; Leutenegger M
    Diabetes Res Clin Pract; 1991 Sep; 13(3):189-98. PubMed ID: 1959482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The value of C-peptide level measurements in diabetes mellitus.
    Rajasoorya C; Tan YT; Chew LS
    Ann Acad Med Singap; 1990 Jul; 19(4):463-6. PubMed ID: 2221804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with long-term oral hypoglycemic agent responsiveness in korean patients with type 2 diabetes mellitus.
    Kim BY; Jung CH; Mok JO; Kim CH
    Diabetes Metab J; 2011 Jun; 35(3):282-9. PubMed ID: 21785749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of perception of insulin therapy among Chinese patients with type 2 diabetes mellitus.
    Chen CC; Chang MP; Hsieh MH; Huang CY; Liao LN; Li TC
    Diabetes Metab; 2011 Nov; 37(5):389-94. PubMed ID: 21458350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Secondary failure to oral hypoglycemic drugs: islet cell function determined by urinary C-peptide].
    Durruty P; García de los Rios M; López G
    Rev Med Chil; 1988 Apr; 116(4):301-7. PubMed ID: 3072638
    [No Abstract]   [Full Text] [Related]  

  • 54. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.
    Fujiwara D; Takahashi K; Suzuki T; Shii M; Nakashima Y; Takekawa S; Yoshida A; Matsuoka T
    J Diabetes Investig; 2013 Nov; 4(6):618-25. PubMed ID: 24843717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of insulin deficiency among initially non-insulin-dependent middle-aged diabetic individuals.
    Laakso M; Sarlund H; Pyörälä K
    Diabetes Care; 1986; 9(3):228-31. PubMed ID: 3525053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa.
    Jingi AM; Noubiap JJ; Essouma M; Bigna JJ; Nansseu JR; Ellong A; Mvogo CE
    Ann Transl Med; 2016 Oct; 4(20):395. PubMed ID: 27867947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stimulated C-peptide and glucose levels as metabolic criteria to use insulin treatment in adult-onset type II diabetes.
    Lee A; Bray GA; Morley JE
    Endocr Pract; 1996; 2(3):183-90. PubMed ID: 15251537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The lean patient with type 2 diabetes: characteristics and therapy challenge.
    P B
    Int J Clin Pract Suppl; 2007 Jun; (153):3-9. PubMed ID: 17594388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus.
    Erkens JA; Herings RM; Stolk RP; Spoelstra JA; Grobbee DE; Leufkens HG
    J Clin Epidemiol; 2002 Apr; 55(4):345-9. PubMed ID: 11927201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database.
    Mazzi S; Ravasio R; Forlani G; Veronese G; Fabbri A; Marchesini G
    Clinicoecon Outcomes Res; 2017; 9():711-720. PubMed ID: 29200880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.